Sagimet Biosciences has announced the progression of its lead candidate, denifanstat, an oral, selective fatty acid synthase (FASN ... in F2/F3 MASH, a complex disease where treatments with ...

The scientists discovered that this subtype-specific effect occurs because the polyunsaturated fatty acid forms a complex with FABP5, which is produced at high levels in triple-negative breast tumors ...

This protective substance has now been isolated from ethanol extracts and identified as a fatty acid/protein complex.